Sign in Create account
Sign in and upgrade to a paid plan to export bulk/block deals as CSV.
Sign in and upgrade to a paid plan to export bulk/block deals as CSV.

KIMIA BIOSCIENCES LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530313
₹32.00
▲ 0.02 (0.06%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
43/100
Moderate
Valuation
30/100
Expensive
Momentum
52/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹151 Cr
PE (TTM)
20.1
Industry median 36.1 (152 companies)
Price to Book
8.5
PEG (TTM)
-1.4
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-29.1
Free Cash Flow
₹3 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-38.46%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-62.13%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-6.73%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-41.06%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-12.13%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.04
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
1.95
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
4.18
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.72%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
6.37%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
9.69%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.31%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
28.50%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
42.54%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.95)
  • Yes Return on equity is 15% or more (42.5%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.1%
Low 30.7500 · High 32.8100
1W return
4.6%
Low 28.1100 · High 32.8100
1M return
9.0%
Low 25.5100 · High 32.8100
52W return
-29.1%
Low 25.5100 · High 32.8100
Lifetime High ₹73.6500 (May 11, 2018)
Lifetime Low ₹5.0000 (May 23, 2016)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
31.3
10D
30.7
20D
30.4
50D
33.8
100D
37.6
200D
41.1

Delivery and volume

Day avg. delivery
83.5%
Week avg. delivery
90.7%
Month avg. delivery
91.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

31.85
Pivot
First resistance32.96
Second resistance33.91
Third resistance35.02
First support30.90
Second support29.79
Third support28.84
Day RSI54.6
Day MFI72.6
Day MACD-0.33
Day MACD signal-1.07

Beta

1M1.97
3M0.84
1Y0.84
3Y0.66

Price change analysis

↑ 9.0%
Over 1 Month
LowHigh
25.5132.81
↓ -29.1%
Over 3 Months
LowHigh
25.5132.81
↓ -29.1%
Over 6 Months
LowHigh
25.5132.81
↓ -29.1%
Over 1 Year
LowHigh
25.5132.81
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 20.1 (own history: 22.2–84.6)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹21 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.0800

Ranks #129 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter74.94%
  • Mutual funds0.38%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 74.94% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.38% in Jun 2026 qtr

All shareholding details →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Laurel Organics Ltd to KIMIA BIOSCIENCES LIMITED

All corporate actions →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Kimia Biosciences Ltd - 530313 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 Company Update Kimia Biosciences Ltd - 530313 - Announcement under Regulation 30 (LODR)-Change in Management
28 Sep 2026 AGM/EGM Kimia Biosciences Ltd - 530313 - Shareholder Meeting / Postal Ballot-Outcome of AGM
4 Sep 2026 AGM/EGM Kimia Biosciences Ltd - 530313 - Intimation Of 33Rd Annual General Meeting Of The Company Proposed To Be Held On September 28, 2026 At 3:00 P.M. Through Video Conferencing/Other Audio Visual Means.
4 Sep 2026 Corp. Action Kimia Biosciences Ltd - 530313 - Intimation Of Cut-Off Date/ Record Date, E-Voting And AGM Date For The 33Rd Annual General Meeting.
4 Sep 2026 Others Kimia Biosciences Ltd - 530313 - Reg. 34 (1) Annual Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (42.5%)

Weaknesses

  • Thin net profit margin (1.7%)
  • High financial leverage (Debt/Equity 1.95)
  • Declining revenue YoY (-12.1%)
  • Declining profit YoY (-41.1%)

Opportunities

Data unavailable.

Threats

  • Down 29.1% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about KIMIA BIOSCIENCES LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.